Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Regen Med. 2010 Jul;5(4):593-603. doi: 10.2217/rme.10.50.

Commercialization challenges associated with induced pluripotent stem cell-based products.

Author information

  • Strategic Management Group, Pfizer Global R&D, 50 Pequot Avenue, MS6025-C4171, New London, CT 06320, USA. devyn.m.smith@pfizer.com

Abstract

Induced pluripotent stem (iPS) cells have generated excitement in the regenerative medicine industry. Products derived from iPS cells could be used in a range of drug discovery and development processes. These nontherapeutic products will continue to be launched over the next 5 years, and provide income and knowledge to drive the therapeutic use of iPS cells forward. While the commercial opportunity for iPS cell-based therapies is potentially large, the looming technical and scientific hurdles must be overcome and, thus, the launch of a therapy based on iPS cells is unlikely to occur until the 2020s. While the launch of a therapeutic is many years away, the business models for commercialization should be well understood and proven based on experience with other non-iPS cell-based therapies (both autologous and allogeneic) that will already be on the market.

PMID:
20632862
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Write to the Help Desk